WO2001004143A3 - Prostase vaccine - Google Patents

Prostase vaccine Download PDF

Info

Publication number
WO2001004143A3
WO2001004143A3 PCT/EP2000/006618 EP0006618W WO0104143A3 WO 2001004143 A3 WO2001004143 A3 WO 2001004143A3 EP 0006618 W EP0006618 W EP 0006618W WO 0104143 A3 WO0104143 A3 WO 0104143A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostase
vaccine
protein
homologues
antigens
Prior art date
Application number
PCT/EP2000/006618
Other languages
French (fr)
Other versions
WO2001004143A2 (en
Inventor
Silva Teresa Cabezon
Davin Clifford Dillon
Original Assignee
Smithkline Beecham Biolog
Corixa Corp
Silva Teresa Cabezon
Davin Clifford Dillon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/352,616 external-priority patent/US6395278B1/en
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Priority claimed from US09/570,737 external-priority patent/US7202342B1/en
Priority claimed from US09/593,793 external-priority patent/US7517952B1/en
Priority claimed from GB0015747A external-priority patent/GB0015747D0/en
Application filed by Smithkline Beecham Biolog, Corixa Corp, Silva Teresa Cabezon, Davin Clifford Dillon filed Critical Smithkline Beecham Biolog
Priority to EP00947977A priority Critical patent/EP1194571A1/en
Priority to AU61587/00A priority patent/AU6158700A/en
Priority to JP2001509752A priority patent/JP2003504080A/en
Priority to CA002378846A priority patent/CA2378846A1/en
Publication of WO2001004143A2 publication Critical patent/WO2001004143A2/en
Publication of WO2001004143A3 publication Critical patent/WO2001004143A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention relates to novel proteins and to their production, from the prostase family. In particular, the invention pertains to a prostase protein or fragment thereof fused to an immunological fusion partner, such as NS1. Such antigens may be formulated to provide vaccines for the treatment of prostate tumours. Novel methods for purifying prostase protein and homologues are also provided.
PCT/EP2000/006618 1999-07-13 2000-07-11 Prostase vaccine WO2001004143A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00947977A EP1194571A1 (en) 1999-07-13 2000-07-11 Prostase vaccine
AU61587/00A AU6158700A (en) 1999-07-13 2000-07-11 Vaccine
JP2001509752A JP2003504080A (en) 1999-07-13 2000-07-11 vaccine
CA002378846A CA2378846A1 (en) 1999-07-13 2000-07-11 Prostase vaccine

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US09/352,616 1999-07-13
US09/352,616 US6395278B1 (en) 1997-02-25 1999-07-13 Prostate specific fusion protein compositions
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US09/439,313 1999-11-12
US44368699A 1999-11-18 1999-11-18
US09/443,686 1999-11-18
US48367200A 2000-01-14 2000-01-14
US09/483,672 2000-01-14
US53685700A 2000-03-27 2000-03-27
US09/536,857 2000-03-27
US56810000A 2000-05-09 2000-05-09
US09/568,100 2000-05-09
US09/570,737 2000-05-12
US09/570,737 US7202342B1 (en) 1999-11-12 2000-05-12 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/593,793 US7517952B1 (en) 1997-02-25 2000-06-13 Compositions and methods for the therapy and diagnosis of prostate cancer
US09/593,793 2000-06-13
US60578300A 2000-06-27 2000-06-27
GB0015747A GB0015747D0 (en) 2000-06-27 2000-06-27 Vaccine
GB0015747.9 2000-06-27
US09/605,783 2000-06-27

Publications (2)

Publication Number Publication Date
WO2001004143A2 WO2001004143A2 (en) 2001-01-18
WO2001004143A3 true WO2001004143A3 (en) 2001-10-11

Family

ID=27579342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006618 WO2001004143A2 (en) 1999-07-13 2000-07-11 Prostase vaccine

Country Status (5)

Country Link
EP (1) EP1194571A1 (en)
JP (1) JP2003504080A (en)
AU (1) AU6158700A (en)
CA (1) CA2378846A1 (en)
WO (1) WO2001004143A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
AU7753700A (en) * 1999-10-07 2001-05-10 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
ES2374620T3 (en) * 2000-06-20 2012-02-20 Corixa Corporation ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
GB0015722D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Sa Vaccine
GB0015736D0 (en) * 2000-06-27 2000-08-16 Smithkline Beecham Biolog Vaccine
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2011009173A1 (en) * 2009-07-23 2011-01-27 Mater Medical Research Institute Cancer immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192626A1 (en) * 1985-02-07 1986-08-27 Smithkline Beecham Corporation Malaria vaccine
WO1998020117A1 (en) * 1996-11-05 1998-05-14 Incyte Pharmaceuticals, Inc. Prostate-specific kallikrein
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192626A1 (en) * 1985-02-07 1986-08-27 Smithkline Beecham Corporation Malaria vaccine
WO1998020117A1 (en) * 1996-11-05 1998-05-14 Incyte Pharmaceuticals, Inc. Prostate-specific kallikrein
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, HAUPL T ET AL: "Activation of monocytes by three OspA vaccine candidates: Lipoprotein OspA is a potent stimulator of monokines.", XP002165775, Database accession no. PREV199799800815 *
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 19, no. 1, 1997, pages 15 - 23, ISSN: 0928-8244 *
NELSON PETER S ET AL: "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 6, 16 March 1999 (1999-03-16), March 16, 1999, pages 3114 - 3119, XP002165774, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1194571A1 (en) 2002-04-10
AU6158700A (en) 2001-01-30
WO2001004143A2 (en) 2001-01-18
JP2003504080A (en) 2003-02-04
CA2378846A1 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
WO1999040188A3 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
WO2001034801A3 (en) Recombinant gelatin in vaccines
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2000075336A3 (en) Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines
MY125202A (en) Vaccine
MY162525A (en) Process for concentration of antibodies and therapeutic products thereof
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2002012341A3 (en) Her-2/neu fusion proteins
UA87093C2 (en) HUMANIZED IMMUNOGLOBULIN SPECIFICALLY BINDING TO BETA AMYLOID PROTEIN (Бβ)
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2002310321A8 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
NO20033673L (en) Fusion protein for secretion of a protein of interest to the supernatant of a bacterial culture
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2001066778A3 (en) Production of foreign polypeptides in plants as viral coat protein fusions
WO2001032882A3 (en) Nucleic acids and proteins from group b streptococcus
WO2001004143A3 (en) Prostase vaccine
MY141459A (en) Recombinant anti-idiotypic antibodies
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
WO2002077648A3 (en) Pathogenic and commensal vaccine antigens
WO2002000708A3 (en) Mutants of prostase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000947977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2378846

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000947977

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947977

Country of ref document: EP